Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056Phase 3Recruiting
- Lead sponsor
- Biohaven Therapeutics Ltd. (Industry)
- Enrollment
- 300 (estimated)
- Start date
- 26 Jun 2026
- Primary completion
- Jan 2028 (estimated)
- Study completion
- 1 Feb 2028
- Last update posted
- 19 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- BHV-1300 Drug
- Placebo Drug
Conditions and primary outcome
- Graves Disease
Primary outcome
Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid function (total T3, free T4 (FT4), & TSH within normal limits) at Week 26. (Week 26)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07661056.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07661056 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.